Presentation is loading. Please wait.

Presentation is loading. Please wait.

Supplemental Figure 5 v A Idarubicin 100 nM Idarubicin 300 nM B C D

Similar presentations


Presentation on theme: "Supplemental Figure 5 v A Idarubicin 100 nM Idarubicin 300 nM B C D"— Presentation transcript:

1 Supplemental Figure 5 v A Idarubicin 100 nM Idarubicin 300 nM B C D
Mcl1 Tubulin 100nM 300nM 3 6 9 12 Incubation (h) p53 1000nM C DMSO DMSO DMSO Incubation (h) 1 2 3 4 6 1 2 3 4 6 1 2 3 4 6 BCL-2 BCL-XL MCL1 Tubulin Idarubicin 1μM Ara-C 100μM Daunorubicin 1μM D Incubation time (h) 2 4 6 2 4 6 2 4 6 Mcl1 Tubulin 100nM 300nM 1000nM

2 Supplemental Figure 5 (A) FDM cells lacking both Bax and Bak were incubated with 100nM and 300nM idarubicin. Noxa and Puma gene expression were assayed by RT-PCR. Results represent the mean +/- SEM of 4 independent experiments. (B) Bak/Bax double knockout FDM cells were exposed to idarubicin at low (100nM), intermediate (300nM) or high (1000nM) concentrations for up to 12 hours. 100nM idarubicin resulted in p53 up-regulation but had no effect on Mcl-1 expression. 1000nM idarubicin caused rapid loss of Mcl-1, but no Tp53 activation. Intermediate concentrations resulted in both up-regulation of Tp53 and down-regulation of Mcl-1. (C) MV4;11 cells were exposed to idarubicin (1µM) or Ara-C (100µM). Idarubicin rapidly suppressed MCL1 without changes to BCL-2 or BCLXL levels. No such changes were seen with cytarabine. (D) p53 knockout FDM cells were exposed to increasing concentrations of idarubicin for up to 6 hours. Mcl1 was rapidly suppressed by higher ( nM) but not lower concentrations of idarubicin (100 nM).


Download ppt "Supplemental Figure 5 v A Idarubicin 100 nM Idarubicin 300 nM B C D"

Similar presentations


Ads by Google